Glaucoma is a chronic eye disease in which the optic nerve is progressively damaged. It is the leading cause of irreversible blindness, affecting 60 million people by 2010. It is critical to detect glaucoma early as glaucomatous vision loss can be slowed down through early intervention. However, a large portion of glaucomatous patients are not aware of their condition until late stage due to the lack of a low cost and easy access screening programme. Therefore, it is highly desirable for a large scale screening of the disease.
ALPACIA offers a solution to the problem by providing a cloud-based service platform for automatic glaucoma tele-screening.
Taking advantage of the rapid growing cloud resources and advanced pattern classification based glaucoma assessment technology, ALPACIA helps to form an integrated ecosystem that connects patients, screening service providers and doctors in a more efficient way, allowing the disease to be detected earlier and enabling early intervention for more efficient intervention and disease management.
The key features of ALPACIA are as follows:
The technology can be used by the following customers/collaborators:
According to the World Health Organization (WHO), more than 285 million people globally are visually impaired due to eye diseases out of which 246 million of whom have low vision and 39 million are blind.
Currently, eye diseases are detected only when a person experiences symptoms such as pain or blurred vision. However, patients with irreversible diseases such as glaucoma have no symptoms until late stages. Hence, early detection and timely intervention is the only way to prevent visual impairment or blindness. Thus there is a need for a population wide screening tool that is reliable, convenient to administer and fast enough to screen a large volume of users.
The use of a cloud-based telemedicine platform brings many persuasive advantages and benefits to customers.